Reported Saturday, Nektar's Rezpegaldesleukin Shows Statistically Significant EASI Improvements In 393-Patient Phase 2b REZOLVE-AD Trial And Proof-Of-Concept In Alopecia Areata At AAD 2026
Benzinga Newsdesk 7 months ago
News
Rezpegaldesleukin demonstrates statistically significant improvement in mean percent EASI improvement across both moderate and severe atopic dermatitis patientsRezpegaldesleukin proof-of-concept data in alopecia areata
- Rezpegaldesleukin demonstrates statistically significant improvement in mean percent EASI improvement across both moderate and severe atopic dermatitis patients
- Rezpegaldesleukin proof-of-concept data in alopecia areata patients presented as a late-breaking research oral presentation
- SAN FRANCISCO, March 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today showcased data in two presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place in Denver, CO.